260 related articles for article (PubMed ID: 33277440)
1. Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies.
Preillon J; Cuende J; Rabolli V; Garnero L; Mercier M; Wald N; Pappalardo A; Denies S; Jamart D; Michaux AC; Pirson R; Pitard V; Bagot M; Prasad S; Houthuys E; Brouwer M; Marillier R; Lambolez F; Marchante JR; Nyawouame F; Carter MJ; Baron-Bodo V; Marie-Cardine A; Cragg M; Déchanet-Merville J; Driessens G; Hoofd C
Mol Cancer Ther; 2021 Jan; 20(1):121-131. PubMed ID: 33277440
[TBL] [Abstract][Full Text] [Related]
2. Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma.
Wu L; Mao L; Liu JF; Chen L; Yu GT; Yang LL; Wu H; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
Cancer Immunol Res; 2019 Oct; 7(10):1700-1713. PubMed ID: 31387897
[TBL] [Abstract][Full Text] [Related]
3. A Cross-Species Reactive TIGIT-Blocking Antibody Fc Dependently Confers Potent Antitumor Effects.
Yang F; Zhao L; Wei Z; Yang Y; Liu J; Li Y; Tian X; Liu X; Lü X; Sui J
J Immunol; 2020 Oct; 205(8):2156-2168. PubMed ID: 32887749
[TBL] [Abstract][Full Text] [Related]
4. TIGIT enhances CD4
Chen F; Xu Y; Chen Y; Shan S
Cancer Med; 2020 May; 9(10):3584-3591. PubMed ID: 32212317
[TBL] [Abstract][Full Text] [Related]
5. TX99 Is a Neutralizing Monoclonal Antibody Against Mouse TIGIT.
Nakamura Y; Naito K; Yamashita-Kanemaru Y; Komori D; Hirochika R; Shibuya A; Shibuya K
Monoclon Antib Immunodiagn Immunother; 2018 Apr; 37(2):105-109. PubMed ID: 29648914
[TBL] [Abstract][Full Text] [Related]
6. Fc-Silent Anti-TIGIT Antibodies Potentiate Antitumor Immunity without Depleting Regulatory T Cells.
Piovesan D; de Groot AE; Cho S; Anderson AE; Ray RD; Patnaik A; Foster PG; Mitchell CG; Lopez Espinoza AY; Zhu WS; Stagnaro CE; Singh H; Zhao X; Seitz L; Walker NP; Walters MJ; Sivick KE
Cancer Res; 2024 Jun; 84(12):1978-1995. PubMed ID: 38635895
[TBL] [Abstract][Full Text] [Related]
7. Nonfucosylation of an anti-TIGIT antibody enhances FcγR engagement, driving innate immune activation and antitumor activity.
Smith AJ; Thurman RE; Zeng W; Grogan B; Lucas S; Gutierrez G; Heiser RA; Wo SW; Blackmarr A; Peterson S; Gardai SJ
Front Immunol; 2023; 14():1280986. PubMed ID: 38022590
[TBL] [Abstract][Full Text] [Related]
8. Selective depletion of tumor-infiltrating regulatory T cells with BAY 3375968, a novel Fc-optimized anti-CCR8 antibody.
Roider HG; Hoff S; Tseng SY; Berndt S; Trautwein M; Filarsky K; Gritzan U; Camps J; Nadler WM; Grudzinska-Goebel J; Ellinger P; Pesch T; Soon CF; Geyer M; Gluske K; Stelte-Ludwig B; Gorjánácz M
Clin Exp Med; 2024 Jun; 24(1):122. PubMed ID: 38856863
[TBL] [Abstract][Full Text] [Related]
9. TIGIT predominantly regulates the immune response via regulatory T cells.
Kurtulus S; Sakuishi K; Ngiow SF; Joller N; Tan DJ; Teng MW; Smyth MJ; Kuchroo VK; Anderson AC
J Clin Invest; 2015 Nov; 125(11):4053-62. PubMed ID: 26413872
[TBL] [Abstract][Full Text] [Related]
10. Increase in activated Treg in TIL in lung cancer and in vitro depletion of Treg by ADCC using an antihuman CCR4 mAb (KM2760).
Kurose K; Ohue Y; Sato E; Yamauchi A; Eikawa S; Isobe M; Nishio Y; Uenaka A; Oka M; Nakayama E
J Thorac Oncol; 2015 Jan; 10(1):74-83. PubMed ID: 25325779
[TBL] [Abstract][Full Text] [Related]
11. Effective Anti-tumor Response by TIGIT Blockade Associated With FcγR Engagement and Myeloid Cell Activation.
Han JH; Cai M; Grein J; Perera S; Wang H; Bigler M; Ueda R; Rosahl TW; Pinheiro E; LaFace D; Seghezzi W; Williams SMG
Front Immunol; 2020; 11():573405. PubMed ID: 33117369
[TBL] [Abstract][Full Text] [Related]
12. An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models.
Chen X; Xue L; Ding X; Zhang J; Jiang L; Liu S; Hou H; Jiang B; Cheng L; Zhu Q; Zhang L; Zhou X; Ma J; Liu Q; Li Y; Ren Z; Jiang B; Song X; Song J; Jin W; Wei M; Shen Z; Liu X; Wang L; Li K; Zhang T
Front Immunol; 2022; 13():828319. PubMed ID: 35273608
[TBL] [Abstract][Full Text] [Related]
13. TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8
Ge Z; Zhou G; Campos Carrascosa L; Gausvik E; Boor PPC; Noordam L; Doukas M; Polak WG; Terkivatan T; Pan Q; Takkenberg RB; Verheij J; Erdmann JI; IJzermans JNM; Peppelenbosch MP; Kraan J; Kwekkeboom J; Sprengers D
Cell Mol Gastroenterol Hepatol; 2021; 12(2):443-464. PubMed ID: 33781741
[TBL] [Abstract][Full Text] [Related]
14. TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
Chauvin JM; Pagliano O; Fourcade J; Sun Z; Wang H; Sander C; Kirkwood JM; Chen TH; Maurer M; Korman AJ; Zarour HM
J Clin Invest; 2015 May; 125(5):2046-58. PubMed ID: 25866972
[TBL] [Abstract][Full Text] [Related]
15. COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade.
Hansen K; Kumar S; Logronio K; Whelan S; Qurashi S; Cheng HY; Drake A; Tang M; Wall P; Bernados D; Leung L; Ophir E; Alteber Z; Cojocaru G; Galperin M; Frenkel M; White M; Hunter J; Liang SC; Kotturi MF
Cancer Immunol Immunother; 2021 Dec; 70(12):3525-3540. PubMed ID: 33903974
[TBL] [Abstract][Full Text] [Related]
16. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity.
Zhang Q; Bi J; Zheng X; Chen Y; Wang H; Wu W; Wang Z; Wu Q; Peng H; Wei H; Sun R; Tian Z
Nat Immunol; 2018 Jul; 19(7):723-732. PubMed ID: 29915296
[TBL] [Abstract][Full Text] [Related]
17. Characterization of ASP8374, a fully-human, antagonistic anti-TIGIT monoclonal antibody.
Shirasuna K; Koelsch G; Seidel-Dugan C; Salmeron A; Steiner P; Winston WM; Brodkin HR; Nirschl CJ; Abbott S; Kinugasa F; Sugahara S; Ohori M; Takeuchi M; Hicklin DJ; Yoshida T
Cancer Treat Res Commun; 2021; 28():100433. PubMed ID: 34273876
[TBL] [Abstract][Full Text] [Related]
18. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Simpson TR; Li F; Montalvo-Ortiz W; Sepulveda MA; Bergerhoff K; Arce F; Roddie C; Henry JY; Yagita H; Wolchok JD; Peggs KS; Ravetch JV; Allison JP; Quezada SA
J Exp Med; 2013 Aug; 210(9):1695-710. PubMed ID: 23897981
[TBL] [Abstract][Full Text] [Related]
19. Immune Exhaustion of T Cells in Alveolar Echinococcosis Patients and Its Reversal by Blocking Checkpoint Receptor TIGIT in a Murine Model.
Zhang C; Lin R; Li Z; Yang S; Bi X; Wang H; Aini A; Zhang N; Abulizi A; Sun C; Li L; Zhao Z; Qin R; Li X; Li L; Aji T; Shao Y; Vuitton DA; Tian Z; Wen H
Hepatology; 2020 Apr; 71(4):1297-1315. PubMed ID: 31410870
[TBL] [Abstract][Full Text] [Related]
20. Mycophenolate mofetil enhances the effects of tacrolimus on the inhibitory function of regulatory T cells in patients after liver transplantation via PD-1 and TIGIT receptors.
Zeng Q; Yuan X; Cao J; Zhao X; Wang Y; Liu B; Liu W; Zhu Z; Dou J
Immunopharmacol Immunotoxicol; 2021 Apr; 43(2):239-246. PubMed ID: 33657960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
